Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Ayala Pharmaceuticals Inc (ADXS)

Ayala Pharmaceuticals Inc (ADXS)
N/A x N/A N/A x N/A
Pre-market by (Cboe BZX)
0.1051 +0.0751 (+250.33%) 02/21/25 [OTC US]
N/A x N/A N/A x N/A
Pre-market 0.1051 unch (unch) 09:30 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.1051
Day High
0.1051
Open 0.1051
Previous Close 0.0300 0.0300
Volume 200 200
Avg Vol 2,705 2,705
Stochastic %K 3.74% 3.74%
Weighted Alpha -48.53 -48.53
5-Day Change +0.0765 (+267.48%) +0.0765 (+267.48%)
52-Week Range 0.0012 - 0.9689 0.0012 - 0.9689
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 4,481
  • Shares Outstanding, K 42,633
  • Annual Sales, $ 10 K
  • Annual Income, $ -48,070 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 1.63
  • Price/Sales 8.16
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.02
  • Most Recent Earnings $-2.96 on 04/16/24
  • Next Earnings Date 02/19/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0270 +289.26%
on 01/29/25
Period Open: 0.0270
0.3400 -69.09%
on 01/29/25
+0.0781 (+289.26%)
since 01/21/25
3-Month
0.0260 +304.23%
on 12/10/24
Period Open: 0.0270
0.7770 -86.47%
on 01/10/25
+0.0781 (+289.26%)
since 11/20/24
52-Week
0.0012 +8,658.33%
on 07/26/24
Period Open: 0.9700
0.9689 -89.15%
on 03/01/24
-0.8649 (-89.16%)
since 02/21/24

Most Recent Stories

More News
Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...

ADXS : 0.1051 (+250.33%)
ADXSD : 3.8500 (+8.45%)
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on...

ADXS : 0.1051 (+250.33%)
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients...

ADXS : 0.1051 (+250.33%)
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the...

ADXS : 0.1051 (+250.33%)
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this...

ADXS : 0.1051 (+250.33%)
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS

Kahn Swick & Foti, LLC and Monteverde & Associates PC announce that, on March 28, 2022, Advaxis, Inc. issued a Supplemental Proxy Statement that includes additional clarifying information about...

ADXS : 0.1051 (+250.33%)
Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update

Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Priced Offering of $5 Million Convertible...

ADXS : 0.1051 (+250.33%)
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update

MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development...

ADXS : 0.1051 (+250.33%)
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development...

ADXS : 0.1051 (+250.33%)
Advaxis Announces Acceptance for Trading on the OTCQX

MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development...

ADXS : 0.1051 (+250.33%)

Business Summary

Ayala Pharmaceuticals Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. It also involved in developing proprietary Lm-based antigen delivery products for patients suffering...

See More

Key Turning Points

3rd Resistance Point 0.1051
2nd Resistance Point 0.1051
1st Resistance Point 0.1051
Last Price 0.1051
1st Support Level 0.1051
2nd Support Level 0.1051
3rd Support Level 0.1051

See More

52-Week High 0.9689
Fibonacci 61.8% 0.5992
Fibonacci 50% 0.4851
Fibonacci 38.2% 0.3709
Last Price 0.1051
52-Week Low 0.0012

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements